טוען...
Rapamycin and Alzheimer disease: a double-edged sword?
Numerous studies have reported that inhibition of MTOR (mechanistic target of rapamycin kinase) clearly reduces Alzheimer disease neuropathological hallmarks in mouse models. This has resulted in calls for the use of the MTOR inhibitor rapamycin for the treatment of dementia in humans. Unfortunately...
שמור ב:
| הוצא לאור ב: | Autophagy |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613906/ https://ncbi.nlm.nih.gov/pubmed/31066320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15548627.2019.1615823 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|